Skip to main content Skip to search Skip to main navigation

EMA: Concept Paper on the Revision of EU GMP Annex 11 on Computerised Systems

On 16 November 2022, the European Medicines Agency EMA published a concept paper on the planned revision of Annex 11 "Computerised Systems". The reason: The existing document of the EU GMP Guideline dates back to 2011 and no longer corresponds to the state of the art in various areas or does not consider increasingly important new technologies for the GMP field, according to the EMA.

In short:

A new focus is to be on data integrity, in particular the requirements for "data in motion", and data in archives or in backup, the so called "data at rest". The requirements for providers of e.g., cloud services are also to go into more detail and the meaning of "validation and qualification of the systems" is to be clarified in greater depth. This also applies to the term "commercial off-the-shelf products". References to ICH Q9 and thus to quality risk management will also be added.

In addition to these classic topics, developments in the field of artificial intelligence will be included in the future. There are currently no regulatory guidelines or expectations for AI (artificial intelligence) or ML (machine learning). The main focus here should be on the relevance, appropriateness and integrity of the data with which these models are tested and, on the results (metrics) of such tests.

Of interest is a reference (33.) to the FDA's draft document "Computer Software Assurance for Production and Quality System Software", which was recently published. This important US document is to be reviewed for possible regulatory relevance to Annex 11.

The timeline for a new Annex 11:
The consultation period ends on 16 January 2023, with a draft document to be released for consultation in December 2024. Finalisation of the document is planned for 2026.


Source:

EMA: Concept paper on EU Annex 11 on Computerised Systems

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
Previous
Next